PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.06%
Positive EBIT growth while CRVO is negative. John Neff might see a substantial edge in operational management.
7.06%
Operating income growth under 50% of CRVO's 212.24%. Michael Burry would be concerned about deeper cost or sales issues.
10.36%
Positive net income growth while CRVO is negative. John Neff might see a big relative performance advantage.
28.30%
EPS growth under 50% of CRVO's 116.32%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
28.30%
Diluted EPS growth under 50% of CRVO's 119.81%. Michael Burry would worry about an eroding competitive position or excessive dilution.
24.68%
Share count expansion well above CRVO's 28.72%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
24.68%
Diluted share count expanding well above CRVO's 6.07%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
17.79%
Positive OCF growth while CRVO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
17.79%
Positive FCF growth while CRVO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19298.96%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-3628.66%
Negative 5Y OCF/share CAGR while CRVO is at 95.51%. Joel Greenblatt would question the firm’s operational model or cost structure.
45.61%
3Y OCF/share CAGR at 50-75% of CRVO's 73.69%. Martin Whitman would suspect weaker recent execution or product competitiveness.
-15204.15%
Negative 10Y net income/share CAGR while CRVO is at 398.13%. Joel Greenblatt sees a major red flag in long-term profit erosion.
97.68%
5Y net income/share CAGR similar to CRVO's 102.49%. Walter Schloss might see both on parallel mid-term trajectories.
59.13%
Below 50% of CRVO's 119.79%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
9892.41%
10Y equity/share CAGR above 1.5x CRVO's 919.05%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
293.35%
5Y equity/share CAGR above 1.5x CRVO's 100.68%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
201.29%
Positive short-term equity growth while CRVO is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
67.39%
Positive asset growth while CRVO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
64.49%
Under 50% of CRVO's 322.92%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
No Data
No Data available this quarter, please select a different quarter.
13.21%
R&D dropping or stable vs. CRVO's 49.15%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-38.56%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.